Viewing StudyNCT04633902



Ignite Creation Date: 2024-05-06 @ 3:26 PM
Last Modification Date: 2024-10-26 @ 1:49 PM
Study NCT ID: NCT04633902
Status: RECRUITING
Last Update Posted: 2022-12-06
First Post: 2020-11-12

Brief Title: Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination HR Mutation
Sponsor: California Pacific Medical Center Research Institute
Organization: California Pacific Medical Center Research Institute

Conditions & Keywords Data

Conditions:
Name
Metastatic Melanoma
Keywords:
Name View
anti PD-1 antibody View
Homologous recombination HR View
Mutation View
Olaparib View
Pembrolizumab View
PARP inhibitor View